News headlines about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1608876050294 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bristol-Myers Squibb Company And Encourages Investors With Losses To Contact The Firm (finance.yahoo.com)
- Lysophosphatidic Acid Receptor 1 Global Key Players – Bristol-Myers Squibb Co, Epigen Biosciences Inc, F. Hoffmann … (businessservices24.com)
- Bristol-Myers Squibb boosts parental leave, expands caregiver benefits (benefitnews.com)
- Ex-Dividend Reminder: Bristol-Myers Squibb, Kite Realty Group Trust and Erie Indemnity (nasdaq.com)
- Johnson & Johnson Stock on March 29, 2018 (finance.yahoo.com)
Shares of BMY opened at $62.98 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. The stock has a market capitalization of $102,477.23, a P/E ratio of 20.92, a P/E/G ratio of 1.63 and a beta of 0.96. Bristol-Myers Squibb has a 12-month low of $51.56 and a 12-month high of $70.05.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.
Several brokerages have recently weighed in on BMY. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, February 16th. Jefferies Group set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, February 26th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. DZ Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Argus reiterated a “buy” rating and set a $66.43 target price (down from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday, March 21st. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $66.68.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Bristol-Myers Squibb (BMY) Share Price” was originally posted by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://baseballnewssource.com/2018/04/05/bristol-myers-squibb-bmy-receiving-somewhat-positive-news-coverage-accern-reports/2025347.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.